Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 209

1.

Kuijieling regulates the differentiation of Treg and Th17 cells to ameliorate experimental colitis in rats.

Long Y, Li S, Qin J, Xie L, Gan L, Jie F, Wu Y, Li Y, Du Q.

Biomed Pharmacother. 2018 Jun 14;105:781-788. doi: 10.1016/j.biopha.2018.06.011. [Epub ahead of print]

PMID:
29909346
2.

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.

Rawla P, Sunkara T, Raj JP.

J Inflamm Res. 2018 May 16;11:215-226. doi: 10.2147/JIR.S165330. eCollection 2018. Review.

3.

Andrographolide affects Th1/Th2/Th17 responses of peripheral blood mononuclear cells from ulcerative colitis patients.

Zhu Q, Zheng P, Zhou J, Chen X, Feng Y, Wang W, Zhou F, He Q.

Mol Med Rep. 2018 Jul;18(1):622-626. doi: 10.3892/mmr.2018.8992. Epub 2018 May 8.

PMID:
29749556
4.

Current, experimental, and future treatments in inflammatory bowel disease: a clinical review.

Hvas CL, Bendix M, Dige A, Dahlerup JF, Agnholt J.

Immunopharmacol Immunotoxicol. 2018 May 10:1-15. doi: 10.1080/08923973.2018.1469144. [Epub ahead of print]

PMID:
29745777
5.

Systemic Inflammatory Responses in Ulcerative Colitis Patients and Clostridium difficile Infection.

Limsrivilai J, Rao K, Stidham RW, Govani SM, Waljee AK, Reinink A, Johnson L, Briggs E, Higgins PDR.

Dig Dis Sci. 2018 Jul;63(7):1801-1810. doi: 10.1007/s10620-018-5044-1. Epub 2018 Apr 12.

PMID:
29644517
6.

Andrographolide presents therapeutic effect on ulcerative colitis through the inhibition of IL-23/IL-17 axis.

Zhu Q, Zheng P, Chen X, Zhou F, He Q, Yang Y.

Am J Transl Res. 2018 Feb 15;10(2):465-473. eCollection 2018.

7.

[Emerging Therapies: What Are Promising in the Near Future?]

Seo GS, Lee SH.

Korean J Gastroenterol. 2018 Feb 25;71(2):81-88. doi: 10.4166/kjg.2018.71.2.81. Review. Korean.

8.

Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease.

Duijvestein M, Battat R, Vande Casteele N, D'Haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG.

Curr Treat Options Gastroenterol. 2018 Mar;16(1):129-146. doi: 10.1007/s11938-018-0175-1. Review.

PMID:
29411220
9.

Intestinal IFN-γ-producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease.

Alfen JS, Larghi P, Facciotti F, Gagliani N, Bosotti R, Paroni M, Maglie S, Gruarin P, Vasco CM, Ranzani V, Frusteri C, Iseppon A, Moro M, Crosti MC, Gatti S, Pagani M, Caprioli F, Abrignani S, Flavell RA, Geginat J.

J Allergy Clin Immunol. 2018 Jan 31. pii: S0091-6749(18)30078-2. doi: 10.1016/j.jaci.2017.12.984. [Epub ahead of print]

10.

Alterations in the mucosa-associated fungal microbiota in patients with ulcerative colitis.

Qiu X, Ma J, Jiao C, Mao X, Zhao X, Lu M, Wang K, Zhang H.

Oncotarget. 2017 Nov 20;8(64):107577-107588. doi: 10.18632/oncotarget.22534. eCollection 2017 Dec 8.

11.

Clinical Significance of Bmi1 Expression in Inflammatory Bowel Disease.

Yamada M, Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Yamao K, Takenaka M, Hagiwara S, Matsui S, Watanabe T, Nishida N, Kashida H, Kudo M.

Oncology. 2017;93 Suppl 1:20-26. doi: 10.1159/000481225. Epub 2017 Dec 20.

12.

Sentinels at the frontline: the role of intraepithelial lymphocytes in inflammatory bowel disease.

Hu MD, Edelblum KL.

Curr Pharmacol Rep. 2017 Dec;3(6):321-334. doi: 10.1007/s40495-017-0105-2. Epub 2017 Aug 22.

PMID:
29242771
13.

Investigation of the relationship between the Th17/IL-23 pathway and innate-adaptive immune system in TNBS-induced colitis in rats.

Karaboga İ, Demirtas S, Karaca T.

Iran J Basic Med Sci. 2017 Aug;20(8):870-879. doi: 10.22038/IJBMS.2017.9108.

14.

Clinical importance of IL-22 cascade in IBD.

Mizoguchi A, Yano A, Himuro H, Ezaki Y, Sadanaga T, Mizoguchi E.

J Gastroenterol. 2018 Apr;53(4):465-474. doi: 10.1007/s00535-017-1401-7. Epub 2017 Oct 26. Review.

15.

The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?

Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG.

J Crohns Colitis. 2018 Jan 5;12(1):105-119. doi: 10.1093/ecco-jcc/jjx117.

PMID:
28961959
16.

A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines.

Zhao Q, Kim T, Pang J, Sun W, Yang X, Wang J, Song Y, Zhang H, Sun H, Rangan V, Deshpande S, Tang H, Cvijic ME, Westhouse R, Olah T, Xie J, Struthers M, Salter-Cid L.

J Leukoc Biol. 2017 Nov;102(5):1271-1280. doi: 10.1189/jlb.5A0717-302. Epub 2017 Sep 12.

PMID:
28899907
17.

miR-155 targets Est-1 and induces ulcerative colitis via the IL-23/17/6-mediated Th17 pathway.

Hou J, Hu X, Chen B, Chen X, Zhao L, Chen Z, Liu F, Liu Z.

Pathol Res Pract. 2017 Oct;213(10):1289-1295. doi: 10.1016/j.prp.2017.08.001. Epub 2017 Aug 25.

PMID:
28888763
18.

Novel therapeutic targets for inflammatory bowel disease.

Argollo M, Fiorino G, Hindryckx P, Peyrin-Biroulet L, Danese S.

J Autoimmun. 2017 Dec;85:103-116. doi: 10.1016/j.jaut.2017.07.004. Epub 2017 Jul 12. Review.

PMID:
28711286
19.

New treatment strategies for ulcerative colitis.

Panés J, Alfaro I.

Expert Rev Clin Immunol. 2017 Oct;13(10):963-973. doi: 10.1080/1744666X.2017.1343668. Epub 2017 Jun 21. Review.

PMID:
28617055
20.

Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles.

Nemeth ZH, Bogdanovski DA, Barratt-Stopper P, Paglinco SR, Antonioli L, Rolandelli RH.

Cureus. 2017 Apr 19;9(4):e1177. doi: 10.7759/cureus.1177.

Supplemental Content

Loading ...
Support Center